Skip Navigation

A Randomized, Open-label, Phase III Study of Mirvetuximab Soravtansine vs. Investigator?s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04209855

Study #:
STUDY00145706

Start Date:
May 05, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04209855

View Complete Trial Details & Eligibility at ClinicalTrials.gov